Pharming Group to report third quarter 2024 financial results on October 24
PHAR Stock | USD 7.74 0.27 3.61% |
Slightly above 55% of Pharming Group's retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Pharming Group NV suggests that some traders are interested. Pharming Group's investing sentiment overview a quick insight into current market opportunities from investing in Pharming Group NV. Many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Pharming |
Leiden, the Netherlands, October 10, 2024 Pharming Group N.V. confirms it will report its preliminary third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 1330 CEST0730 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in inform
Read at finance.yahoo.com
Pharming Group Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Pharming Group can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Pharming Group is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
JANX | Janux Therapeutics | 11.64 | ||||
ANEB | Anebulo Pharmaceuticals | 7.64 | ||||
MOLN | Molecular Partners | 5.81 | ||||
GNTA | Genenta Science | 2.54 | ||||
VRCA | Verrica Pharmaceuticals | 0.85 | ||||
LRMR | Larimar Therapeutics | 0.16 | ||||
ELYM | Eliem Therapeutics | 0.31 | ||||
PRTC | PureTech Health | 2.23 | ||||
MLYS | Mineralys Therapeutics, | 2.49 | ||||
FENC | Fennec Pharmaceuticals | 2.57 | ||||
RZLT | Rezolute | 3.55 | ||||
OPT | Opthea | 4.24 | ||||
ACRV | Acrivon Therapeutics, | 9.66 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.